Pfizer Inc PFE

$30.52 +0.57 (1.90%)

Valuation

Market cap
167,855,392,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.77
Forward PE
10.12
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
45,485,400
Avg volume
31,372,070
Day's range
$30.14 – $30.67
Shares out
5,699,674,000
Stochastic %K
60%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

RocroBio Oct 30, 10:15 PM 0 replies
jonecho49 Oct 30, 9:57 PM
$PFE All the talking heads today say the big pharma cos with Lilly as king are still a place to invest in. PFE never mentioned, never highlighted, never covered. I kinda like this actually. Lets hope for 40+ this coming year or into 50s in 2 years.
1 replies
1of402Phase2TrialUSA Oct 30, 9:43 PM
$INO $MRNA $$SPY $PFE Inovio beat the majors to the 1st DNA Medicine FDA approved in the World. With a big pipeline of Cancer killing Vaccines. Awarded today after trading! Congrats Inovio!!!! Let’s devour those 30% of float Shirts Monday morning. I’m good with $25 a share🚀🚀🚀
1 replies
DrMcSavage Oct 30, 9:42 PM
$PFE next Tuesday 11/3 wow big day for this chart. It’s going to make or break it. Earnings report BMO
1 replies
MJStock Oct 30, 9:35 PM
$TGTX $PFE was nicely green today also
1 replies
davidmoadel Oct 30, 9:28 PM
The Drug Patent Cliff: Which Pharmaceutical Stocks Have the Most to Lose? -- my article for MarketScreener https://marketscreener.com/news/the-drug-patent-cliff-which-pharmaceutical-stocks-have-the-most-to-lose-ce785fdad981f223 $MRK $BMY $PFE @Marketscreener_US
0 replies
gogogomm Oct 30, 8:16 PM
$PFE fda approved ketafree(*new ketamin) $NRXP Commercial Milestone: NRx Pharmaceuticals secured FDA approval for preservative-free ketamine in under 14 months, marking its transition to a commercial-stage pharmaceutical company. ​Technology & Margin Innovation: By using advanced Blow-Fill-Seal (BFS) technology and removing toxic preservatives (BZT), NRx eliminated expensive glass bottling to achieve profit margins rivaling new innovative drugs. ​Market Strategy: Capitalizing on chronic U.S. drug shortages, the company will leverage guaranteed domestic supply (partnered with Nephron) to capture the $400M hospital and clinic ketamine market. good
0 replies
Diehard777 Oct 30, 7:45 PM 0 replies